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Abstract
Background: Recent data have shown that γδ T cells can act as mediators for immune defense against tumors.
Our previous study has demonstrated that persisting clonally expanded TRDV4 T cells might be relatively beneficial
for the outcome of patients with T cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation
(HSCT). However, little is known about the distribution and clonality of the TRDV repertoire in T cell receptor (TCR)
of γδ T cells and their effects on the clinical outcome of patients with acute myeloid leukemia (AML). The aim of
this study was to assess whether the oligoclonal expansion of TCR Vδ T cells could be used as an immune
biomarker for AML outcome.
Findings: γδ T cells were sorted from the peripheral blood of 30 patients with untreated AML and 12 healthy donors.
The complementarity-determining region 3 (CDR3) sizes of eight TCR Vδ subfamily genes (TRDV1 to TRDV8) were
analyzed in sorted γδ T cells using RT-PCR and GeneScan. The most frequently expressed TRDV subfamilies in the AML
patients were TRDV8 (86.67 %) and TRDV2 (83.33 %), and the frequencies for TRDV1, TRDV3, TRDV4, and TRDV6 were
significantly lower than those in healthy individuals. The most frequent clonally expanded TRDV subfamilies in the AML
patients included TRDV8 (56.67 %) and TRDV4 (40 %). The clonal expansion frequencies of the TRDV2 and TRDV4 T cells
were significantly higher than those in healthy individuals, whereas a significantly lower TRDV1 clonal expansion
frequency was observed in those with AML. Moreover, the oligoclones of TRDV4 and TRDV8 were independent
protective factors for complete remission. Furthermore, the oligoclonal expansion frequencies of TRDV5 and TRDV6 in
patients with relapse were significantly higher than those in non-recurrent cases.
Conclusions: To the best of our knowledge, we characterized for the first time a significant alteration in the
distribution and clonality of the TRDV subfamily members in γδ T cells sorted from AML patients. Clonally expanded
TRDV4 and TRDV8 T cells might contribute to the immune response directed against AML, while oligoclonal TRDV5 and
TRDV6 might occur in patients who undergo relapse. While the function of such γδ T cell clones requires further
investigation, TRDV γδ T cell clones might be potential immune biomarkers for AML outcome.
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Introduction
Acute myeloid leukemia (AML) is a fast-growing malig-
nant hematological disease that occurs in large, immature
white blood cells [1]. The immune systems of patients
with AML become uncontrolled, leading to leukemia that
cannot develop normal-functioning blood cells. Although
treatments for curing AML, such as chemotherapy and
hematopoietic stem cell transplantation (HSCT), have
appeared in recent years, the outcome of some patients
who are unable to undergo intensive chemotherapy and
HSCT remains dismal with a poor survival of only 5 to
10 months [2, 3]. Therefore, novel strategies such as cellu-
lar immunotherapy have been proposed and increasingly
investigated.
In the past decade, there have been numerous efforts
toward developing specific T cell-based immunother-
apies to manage cancer [4–6]. γδ T cells are a T cell
subset that comprise approximately 5–10 % of all per-
ipheral T cells in healthy individuals [7]. Due to the anti-
tumor function of γδ T cells, they have been proposed to
have therapeutic potential for cancer treatment [8–10].
Several in vivo and in vitro data have demonstrated that
γδ T cells are excellent candidates for further improving
immunotherapy efficacy because of their intrinsic char-
acteristics and function [11, 12]. Accumulating evidence
supports a particular antitumor cytotoxicity value for γδ
T cells in the development of immunotherapy-based ap-
proaches for hematological malignancies such as myelo-
dysplastic syndromes (MDS), multiple myeloma (MM),
and chronic myeloid leukemia (CML) [13–15]. Despite
encouraging preclinical studies of some hematological
malignancies, γδ T cell-based immunotherapy for AML
patients remains in its infancy, and the immune charac-
teristics of γδ T cells in AML require further elucidation.
Recent insights into the structure of the γδ T cell recep-
tor (TCR) and its ligands strongly indicate that γδ T cells
possess unique functions for defending hosts against an
extensive range of infections and stresses [7, 10, 16]. A
growing body of evidence demonstrates that γδ T cells
can act as functional agents for immune defense against
tumors or pathogenic invaders in inflammatory reactions;
they perform different functions based on their tissue
distribution, antigen–receptor structure, and local micro-
environment [17]. Recently, it has been reported that the
phenotype and distribution of γδ T cells in human breast
cancer might serve as a prognostic factor predicting
clinical outcome [18]. Our previous study reported that
clonally expanded TRDV4 T cells might lead to rela-
tively better outcome for patients diagnosed with T –
cell acute lymphoblastic leukemia (T-ALL) after HSCT
[19]. However, little is known about the correlation
between γδ T cells and AML outcome. In this study, we
analyze the distribution and clonality of TRDV subfam-
ilies in γδ T cells sorted from the peripheral blood (PB)
and discuss the clinical relevance of γδ T cell subfam-
ilies in AML patients.
Results
Expression frequency and clonality of TCR Vδ T cells in AML
In this study, the complementarity-determining region 3
(CDR3) sizes of eight TRDV subfamily genes were
analyzed in γδ T cells sorted from peripheral blood
mononuclear cells (PBMCs) from 30 patients with AML
and 12 healthy individuals using RT-PCR and GeneScan
(Fig. 1). Approximately, 25–75 % of the TRDV subfam-
ilies were expressed in 30 different AML patients. The
mean value of the number of expressed TRDV subfam-
ilies was 4.40 ± 1.07, which was significantly lower than
that in healthy individuals (6.67 ± 1.23, P = 0.000). The
most frequently expressed subfamilies in the AML pa-
tients were TRDV8 (26/30; 86.67 %) and TRDV2 (25/30;
83.33 %). TRDV6 was detected in only 11 patients (11/
30; 36.67 %), and the frequencies of TRDV1, TRDV3,
TRDV4, and TRDV6 were significantly lower than those
in healthy individuals (P = 0.000, 0.031, 0.037, and 0.015,
respectively) (Fig. 2a).
The majority of the TRDV subfamilies in the γδ T cells
displayed polyclonal expansion with a Gaussian distribu-
tion of CDR3 lengths (multi-peaks) corresponding to a
polyclonal rearrangement pattern. PCR product analysis
produced a single dominant peak or double peaks, which
demonstrate a skewed spectratype profile termed “oligo-
clonality” or “biclonality”, respectively. “Oligoclonality
trending” is a classification with a profile between that of
polyclonality and oligoclonality [19]. Clonal expansion
was detected for all eight TRDV subfamilies in the γδ T
cells. Greater than two TRDV subfamilies demonstrated
oligoclonality, biclonality, or oligoclonality trending in
all of the AML samples. In addition, the oligoclonally
expanded γδ T cells were distributed in almost all of the
TRDV subfamilies in the AML patients with the excep-
tion of TRDV1 (6.67 %, 2/30), and the most frequently
oligoclonally expanded TRDV subfamilies were TRDV8
(17/30, 56.67 %) and TRDV4 (12/30, 40 %). The clonal
expansion frequencies of the TRDV2 and TRDV4 sub-
families were significantly higher than those in healthy
individuals (P = 0.012 and P = 0.009); however, a signifi-
cantly lower clonal expansion frequency for TRDV1 was
observed in the AML patients (P = 0.046) (Fig. 2b).
Clinical relevance of the oligoclonal expansion of TCR Vδ
T cells in AML
The association between AML outcome, the clonality of
TRDV subfamilies in γδ T cells, age, WBCs, blast cell
percentage in PB, and the absolute number of γδ T cells in
PB was analyzed by multivariate non-conditional logistic
regression analysis and multivariate stepwise regression
analysis. The results demonstrated that oligoclonal
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expansion of the TRDV4 and TRDV8 subfamilies are inde-
pendent protective factors (odds ratio (OR) = 0.137, 95 %
confidence interval (CI) 0.015–1.210; OR = 0.067, 95 % CI
0.005–0.843), and the percentage of blast cells in PB was
an independent risk factor for complete remission (CR)
(OR = 1.047, 95 % CI 1.009–1.087).
We also observed that seven patients underwent
relapse after achieving CR. In addition, we compared
differences in the oligoclonal expansion of TRDV sub-
families between those with recurrence and those with
non-recurrence. Interestingly, the oligoclonal expansion
frequencies of TRDV5 and TRDV6 in the recurrence
group were significantly higher than those in the non-
recurrence group (P = 0.031 and P = 0.007) (Figs. 3 and 4).
Logistic regression analysis demonstrated that oligoclonal
expansion of TRDV5 and TRDV6 was an independent risk
factor for AML recurrence (OR = 21.822, 95 % CI 1.426–
333.877; OR = 44.603, 95 % CI 2.169–917.358, respectively).
Discussion
Although treatments for curing AML have appeared in
recent years, the clinical outcomes of some AML patients
have not been positive. Recent studies have suggested that
there were restricted distribution and clonality for the
TRDV subfamilies in different diseases including immune
thrombocytopenic purpura, B cell non-Hodgkin lymph-
oma, allergic rhinitis, MDS, CML, and graft versus host
disease (GVHD) [20–25]. Understanding the mechanisms
Fig. 1 Distribution and clonality of the TRDV subfamilies in γδ T cells. a 12 healthy individuals. b 30 AML patients
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underlying the γδ T cell immune response in patients with
leukemia is vital for developing strategies for leukemia
immunotherapy [26–28]. To investigate the immune char-
acteristics of γδ T cells in patients with AML, we first
sorted the γδ T cells from the PB of AML patients and
analyzed their TCR Vδ repertoire. We then attempted to
characterize the correlation between oligoclonal expansion
of TCR Vδ repertoire and clinical outcome.
In PB T cells from healthy individuals, the TRDV
repertoire expression pattern is unrestricted. In contrast,
we found significantly restricted TRDV subfamily expres-
sion in the γδ T cells from patients with AML. Such an
alteration in the TRDV repertoire distribution in AML
appeared to be different for different diseases, e.g., the
most frequently expressed TRDV genes were TRDV1
and TRDV2 followed by TRDV8 and TRDV3 in MDS
patients [22]. This observation suggests that different
subfamilies of γδ T cells might be preferentially active in
different diseases and different immune statuses for
patients with the same disease.
In immunodeficient patients with leukemia, it is diffi-
cult to distinguish the role of oligoclonal T cells, which
may serve as reactive T cell clones directed against
leukemia. In contrast, there may be clonal absence be-
cause T cell proliferation is suppressed by different factors
in leukemia. For example, TRDV2 T cells are reduced and
dysfunctional in some MDS patients [15, 19, 29]. To
further investigate the role of oligoclonal TRDV T cells in
AML patients, we first analyzed the correlation between
clonally expanded TRDV T cells and clinical outcome. We
found that different oligoclonal TRDV subfamily T cells
might have unique functions. We found that the clonal
expansion patterns of TRDV4 and TRDV8 T cells might
be independent protective factors for CR, which is consist-
ent with our previous findings in which we found that
clonally expanded TRDV4 T cells might be related to bet-
ter outcome for a T-ALL patient [19]. We suggested that
such expanded TRDV4 and TRDV8 T cell clones might be
reactive T cell clones directed against leukemia that serve
as biomarkers for the therapeutic efficacy of AML
patients. However, a higher frequency of clonally ex-
panded TRDV8 was also found in MDS patients who
developed AML [22]. Thus, further investigation is needed
to characterize the function of TRDV8 T cell clones in
vitro and in vivo. Interestingly, we also found that TRDV5
and TRDV6 T cells might be related to AML recurrence.
These oligoclonal TRDV5 and TRDV6 T cells might be in-
dicators of minimal residual disease in AML patients.
However, this hypothesis requires confirmation with a lar-
ger cohort.
In conclusion, to the best of our knowledge, this is the
first attempt to analyze the distribution and clonality of
the TRDV repertoire in γδ T cells in AML patients. Al-
terations in the peripheral TRDV gene repertoire are an
important characteristic of γδ T cells in AML patients,
which may be related to the immune response, antileu-
kemia effects, and patient outcome. These findings
might provide new data regarding the characteristics of
cellular immunity in AML patients. The oligoclonal
expansion of TCR Vδ T cells may serve not only as an
Fig. 3 Oligoclonal expansion frequencies of the TRDV subfamilies in
γδ T cells from AML patients (using the Fisher’s exact test)
Fig. 2 Frequencies of the TRDV subfamilies in γδ T cells from AML patients and healthy individuals (using the Fisher’s exact test). a Expression
frequencies. b Clonal expansion frequencies
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immune biomarker for clinical outcome but also as an
antileukemia immune status indicator in AML patients.
Based on this study, we will further investigate the func-
tion of the TCR Vδ T cells subfamilies in co-culture
models and mouse xenograft model.
Materials and methods
Samples
After obtaining patient consent, PBMCs from 30 AML
patients (17 males and 13 females, median age 33 years,
range 17–67 years) was collected. The diagnosis of AML
was based on the French–American–British (FAB) cri-
teria: 6 patients were classified as M0, 1 patient was M1, 5
patients were M2, 10 patients were M3, 3 patients were
M4, and 5 patients were M5. Twelve healthy individuals
(5 males and 7 females, median age 41 years, range 29–
62 years) served as the control group. The clinical data of
the patients are listed in Additional file 1: Table S1.
This study was approved by the Ethics Committee of
the Medical School of Jinan University of Guangdong
Province in China, and all procedures were conducted
according to the guidelines of the Medical Ethics
Committees of the Health Bureau of the Guangdong
Province of China.
γδ T cell sorting
The γδ T cells in the PB from 30 AML patients and 12
healthy individuals were sorted by using γδ monoclonal
antibodies and the MACS magnetic cell sorting technique
(Miltenyi Biotec, Bergisch Gladbach, Germany) [30].
RNA isolation and cDNA synthesis
RNA was extracted from the sorted γδ T cells using TRI-
zol RNA extraction buffer according to the manufacturer’s
Fig. 4 GeneScan results of the TRDV subfamily members in γδ T cells from AML cases with recurrence
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protocol (Invitrogen, Carlsbad, CA, USA). The quality of
the RNA was analyzed in a 1.5 % agarose gel stained with
ethidium bromide. Two micrograms of RNA was reverse
transcribed into first-strand complementary DNA (cDNA)
with random hexamer primers using the reverse tran-
scriptase of the SuperScript II Kit (Gibco, Gaithersburg,
MD, USA). The cDNA quality was confirmed by RT-PCR
of the β2 microglobubin (β2M) gene [31].
TRDV subfamily expression analysis by RT-PCR
Eight sense TRDV sense primers and a single TRDC
reverse primer were used in unlabeled PCR to amplify
the TRDV subfamilies. Subsequently, runoff PCR was
performed with fluorescent primers labeled at the 5' end
with a FAM fluorophore (Cδ-FAM), which was pur-
chased from TIB MOLBIOL GmbH, Berlin, Germany.
The sequences of the primers are listed in Additional file 2:
Table S2. PCR was performed as previously described [22].
The cDNA aliquots (1 μl) were amplified in 20 μl reactions
using one of the eight Vδ primers and a Cδ primer. The
final reaction mixture contained 0.5 μM sense and anti-
sense primers, 0.1 mM dNTPs, 1.5 mM MgCl2, 1× PCR
buffer, and 1.25 U Taq polymerase (Promega, Foster
City, CA, USA). Amplification was performed with a
thermal cycler (BioMetra, Germany). After a 3-min de-
naturation at 94 °C, 40 cycles of 94 °C for 1 min, 60 °C
for 1 min, and 72 °C for 1 min were performed followed
by a final 6-min elongation at 72 °C. The products were
then stored at 4 °C [32].
TRDV subfamily clonality identification by GeneScan
analysis
Aliquots of unlabeled PCR products (2 μl) were subjected
to a runoff reaction cycle using a fluorophore-labeled Cδ-
FAM primer. The labeled runoff PCR products (2 μl) were
heat-denatured at 94 °C for 4 min with 9.5 μl formamide
(Hi-Di Formamide, ABI, USA) and 0.5 μl size standards
(GENESCAN™-500-LIZ™, Perkin Elmer, ABI). The sam-
ples were then loaded in a 3100 POP-4™ gel (Performance
Optimized Polymer-4, ABI, USA) and resolved by electro-
phoresis with a 3100 DNA sequencer (ABI, PerkinElmer)
for size and fluorescence intensity determination using
GeneScan software [33–35].
Statistical analysis
All data analyses, including statistical calculations and
graphical displays, were performed using SPSS 13.0 and
GraphPad software. Univariate analysis was performed
using the Mann–Whitney test to compare the means of
the expression of the clonally expanded TRDV subfam-
ilies between AML patients and healthy individuals. Dif-
ferent frequencies of TRDV subfamilies were compared
using Fisher’s exact test. Oligoclonal TRDV expansion
differences between the recurrence and non-recurrence
groups were measured using the Fisher’s exact test.
Binary logistic regression analysis was performed to
determine associations between the clonal expansion of
γδ T cells and the outcome of the AML patients. All
analyses included the following variables: γδ T cell clonal
expansion, age, WBC count, percentage of blast cells in
PB, absolute number of γδ T cells in PB, and clinical
status. Odds ratios and 95 % confidence intervals were
also calculated. Only values with P < 0.05 were consid-
ered statistically significant.
Additional files
Additional file 1: Table S1. AML patient characteristics. (DOCX 15 kb)
Additional file 2: Table S2. List of primer sequences used for the TRDV
subfamilies. (DOCX 13 kb)
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